ATOR-1017

ATOR-1017 is described in the provided pipeline context as an early-stage, tumor-directed immuno-oncology program targeting the CD40 pathway. CD40 is a co-stimulatory receptor expressed on antigen-presenting cells (APCs), such as dendritic cells and macrophages; its activation is essential for the induction of potent anti-tumor T-cell responses. This program utilizes agonistic monoclonal and bispecific antibody formats designed to trigger CD40 signaling, aiming to enhance the tumor microenvironment and promote systemic immunity against solid tumors. Note: While this specific pipeline entry associates ATOR-1017 with CD40, clinical data and other sources identify ATOR-1017 (evunzekibart) as a 4-1BB (CD137) agonist. This description focuses on the CD40-targeting attributes as specified in the request.